Clinical Trials

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02213913 2026-03-11

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Phase 1/2 Completed

55 enrolled 17 charts

Phase 1/2 Active not recruiting

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Intraocular Lymphoma

NCT04623541 2026-03-04

EPCORE™ CLL-1

195 enrolled

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04542824 2026-03-03

EPCORE™ NHL-3

78 enrolled

Phase 2 Active not recruiting

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT01446133 2026-01-27

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

120 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01496976 2025-12-19

Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL

45 enrolled 12 charts

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02005289 2025-12-15

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

41 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT02568553 2025-11-26

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

35 enrolled

Phase 2 Active not recruiting

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01351896 2025-11-20

Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

49 enrolled 34 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01995669 2025-06-24

Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma

Phase 1/2 Completed

66 enrolled 13 charts

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT00848328 2025-04-24

Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma

30 enrolled

Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04578600 2025-04-24

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

8 enrolled

Phase 1/2 Enrolling by invitation

Leukemia, Hairy Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06762431 2025-01-07

VTB-CLL002

60 enrolled

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01199575 2024-08-15

Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

30 enrolled 12 charts

Phase 1 Active not recruiting

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06547944 2024-08-09

ZGR in TN CLL

30 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01754857 2023-06-27

Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

36 enrolled 11 charts

Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02280525 2023-06-07

Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma

8 enrolled

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00783367 2023-03-30

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

50 enrolled 11 charts

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02225275 2022-09-28

Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

9 enrolled 9 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01886859 2022-09-26

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

27 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, B-Cell

NCT03379051 2022-08-22

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

Phase 1/2 Terminated

78 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01241786 2022-07-20

VZCLLPI0146

5 enrolled 10 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01744912 2022-05-11

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

Phase 1 Terminated

10 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01125176 2022-01-21

ThRiL

15 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01556776 2022-01-05

A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy

Phase 3 Completed

89 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00774345 2021-12-02

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

Phase 3 Completed

317 enrolled 13 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00792077 2021-07-01

A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue

6 enrolled 10 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01497496 2021-04-27

Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

29 enrolled 9 charts

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01088048 2021-03-18

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

241 enrolled 31 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02309515 2021-01-19

Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis

12 enrolled 8 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01003769 2020-06-16

Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia

Phase 1/2 Terminated

5 enrolled 7 charts